Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

scientific article

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.74.10.4746-4754.2000
P932PMC publication ID111997
P698PubMed publication ID10775613
P5875ResearchGate publication ID24512617

P50authorPeter KolchinskyQ89888879
Richard T. WyattQ96247131
Joseph SodroskiQ64524473
Peter D. KwongQ68690794
P2093author name stringX Yang
M Farzan
L Florin
P2860cites workToward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodiesQ77839425
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and ImmunogensQ22242262
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled ReceptorQ22242268
Identification of a major co-receptor for primary isolates of HIV-1Q22251282
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccinesQ24531479
Crystal structure of SIV matrix antigen and implications for virus assemblyQ27729336
Structure of influenza haemagglutinin at the pH of membrane fusionQ27730888
A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutantsQ27731470
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assemblyQ27732646
Core structure of gp41 from the HIV envelope glycoproteinQ27736064
Atomic structure of the ectodomain from HIV-1 gp41Q27738021
Atomic structure of a thermostable subdomain of HIV-1 gp41Q27746904
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyQ27759364
Structure of the hemagglutinin precursor cleavage site, a determinant of influenza pathogenicity and the origin of the labile conformationQ27766025
Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomainQ27766228
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactorsQ28118386
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusQ28259668
Structural interactions between chemokine receptors, gp120 Env and CD4Q28275632
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolatesQ28282895
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug targetQ28369397
Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoproteinQ28646759
Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41Q28646771
Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicryQ28646789
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1Q28646812
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAVQ28646817
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusionQ28646828
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoproteinQ28646850
A spring-loaded mechanism for the conformational change of influenza hemagglutininQ28646856
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1Q28646859
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5Q29616094
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificityQ33782556
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomainQ33784051
Expression of a synthetic bovine rhodopsin gene in monkey kidney cellsQ34376551
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.Q35839973
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.Q35854300
Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.Q35857331
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodiesQ35930918
Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.Q36549220
Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodiesQ36620408
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.Q36627098
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.Q36633402
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope proteinQ36684443
Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia virusesQ36687749
Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion.Q36796384
The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coilQ37377729
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoproteinQ37675018
Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptorQ38320237
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replicationQ39595771
Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.Q39868309
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralizationQ40059024
Why do we not have an HIV vaccine and how can we make one? .Q40859536
Mutational analysis of the assembly domain of the HIV-1 envelope glycoproteinQ41544160
The antibody response in HIV-1 infection.Q41694946
The human immunodeficiency virus type 1 envelope glycoprotein precursor acquires aberrant intermolecular disulfide bonds that may prevent normal proteolytic processingQ41712188
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patientsQ41936910
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine EvQ45771982
Genetic and Immunologic Characterization of Viruses Infecting MN‐rgp120‐Vaccinated VolunteersQ46675205
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.Q48378749
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene.Q55244821
HIV-1 antibody--debris or virion?Q73206011
P433issue10
P304page(s)4746-4754
P577publication date2000-05-01
P1433published inJournal of VirologyQ1251128
P1476titleModifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
P478volume74

Reverse relations

cites work (P2860)
Q37423302A chimeric protein of simian immunodeficiency virus envelope glycoprotein gp140 and Escherichia coli aspartate transcarbamoylase
Q45409784A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
Q36149102A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.
Q37252789A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140.
Q35110976A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene
Q28299280A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies
Q36363866A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays
Q40503787A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
Q42837168A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells
Q27489000Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates
Q36600380Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.
Q40411001An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor
Q37438501An autoinhibited coiled-coil design strategy for split-protein protease sensors
Q53877712Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.
Q43759388Antiviral drugs with extra-cellular sites of action
Q39896978Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins
Q41579136Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins
Q39370718CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity
Q37730009CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor
Q34471760Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
Q45046883Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle
Q80952728Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d
Q35857631Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity
Q36673173Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses
Q33806056Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
Q41493875Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker
Q37596552Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1
Q39484948Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates
Q52721542Comparison of Uncleaved and Mature Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimers.
Q37834097Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies
Q92727230Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting
Q34465510Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles
Q30342130DNA vaccines against human immunodeficiency virus type 1.
Q34706815Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env.
Q37695592Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers
Q45737326Differential recognition of epitopes present on monomeric and oligomeric forms of gp160 glycoprotein of human immunodeficiency virus type 1 by human monoclonal antibodies
Q35691113Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization
Q40292429Dominant-negative effect of hetero-oligomerization on the function of the human immunodeficiency virus type 1 envelope glycoprotein complex.
Q33571825Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein
Q44614090Effects of HIV Type 1 Envelope Glycoprotein Proteolytic Processing on Antigenicity
Q35596474Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer
Q37422543Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
Q44592226Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan
Q30393406Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin
Q36473515Enhancement of gp120-Specific Immune Responses by Genetic Vaccination with the Human Immunodeficiency Virus Type 1 Envelope Gene Fused to the Gene Coding for Soluble CTLA4
Q34332728Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
Q40471543Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Q42959357Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1.
Q33883887Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
Q37649155Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoprotein.
Q38992740Evolution of B cell analysis and Env trimer redesign
Q45006426Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1.
Q47925878Expression and characterization of recombinant S2 subunit of SARS-coronavirus S fusion protein
Q38309325Expression, purification, and characterization of gp160e, the soluble, trimeric ectodomain of the simian immunodeficiency virus envelope glycoprotein, gp160.
Q45736020Expression, purification, and characterization of recombinant HIV gp140. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufficient to maintain the retroviral envelope glycoprotein as a trimer
Q27676847Extensive Mutagenesis of the HSV-1 gB Ectodomain Reveals Remarkable Stability of Its Postfusion Form
Q39521335Flow cytometry based identification of simian immunodeficiency virus Env-specific B lymphocytes
Q33780529Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin
Q35139607Fusion-induced apoptosis contributes to thymocyte depletion by a pathogenic human immunodeficiency virus type 1 envelope in the human thymus
Q40626990Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.
Q35883997HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost
Q83168652HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies
Q38665463HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies
Q59339672HIV-1 vaccine design through minimizing envelope metastability
Q34999293Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin
Q29619015Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
Q24679395Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design
Q35171701Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization
Q44646864Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies
Q33836042Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
Q51009640Improved expression of secretory and trimeric proteins in mammalian cells via the introduction of a new trimer motif and a mutant of the tPA signal sequence
Q38708708Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.
Q41447893Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers
Q40468582Inter-subunit disulfide bonds in soluble HIV-1 envelope glycoprotein trimers.
Q44925938Isolation and characterization of the Mason-Pfizer monkey virus p12 protein
Q39725329Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function
Q30399285Microneedle vaccination with stabilized recombinant influenza virus hemagglutinin induces improved protective immunity
Q27637675Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex
Q37633417Native-like Env trimers as a platform for HIV-1 vaccine design
Q39684388Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein
Q35826692Optimization of HIV-1 Envelope DNA Vaccine Candidates within Three Different Animal Models, Guinea Pigs, Rabbits and Cynomolgus Macaques
Q37094429Polyvalent AIDS Vaccines
Q36736400Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens
Q64080897Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus
Q35085066Probing the HIV gp120 envelope glycoprotein conformation by NMR.
Q36954218Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras
Q64983102Protein and Glycan Mimicry in HIV Vaccine Design.
Q34332284Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus
Q39484956Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate
Q30353580Recent advances on the use of structural biology for the design of novel envelope immunogens of HIV-1
Q35033862Receptor binding domain based HIV vaccines.
Q40468601Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
Q34279140Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure
Q37415987Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins
Q34334135Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins
Q40397998Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis
Q40210715Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1.
Q34361680Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.
Q30490942Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
Q30447936Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1
Q48009341Structural characterization of the SARS-coronavirus spike S fusion protein core.
Q36246403Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
Q27653846Structure of the HIV-1 gp41 Membrane-Proximal Ectodomain Region in a Putative Prefusion Conformation † , ‡
Q45421033Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation
Q39602726Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers
Q34987048Structure-based vaccine design in HIV: blind men and the elephant?
Q40414065The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles
Q34391256Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Q43932246Trimeric membrane-anchored gp41 inhibits HIV membrane fusion.
Q37060986Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability.
Q39585034Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits
Q36602273Virus-like particles: designing an effective AIDS vaccine

Search more.